Literature DB >> 34338672

A Large Animal Model for Pulmonary Hypertension and Right Ventricular Failure: Left Pulmonary Artery Ligation and Progressive Main Pulmonary Artery Banding in Sheep.

Rei Ukita1, John W Stokes1, W Kelly Wu1, Jennifer Talackine1, Nancy Cardwell1, Yatrik Patel1, Clayne Benson2, Caitlin T Demarest1, Erika B Rosenzweig3, Keith Cook4, Emily J Tsai5, Matthew Bacchetta6.   

Abstract

Decompensated right ventricular failure (RVF) in pulmonary hypertension (PH) is fatal, with limited medical treatment options. Developing and testing novel therapeutics for PH requires a clinically relevant large animal model of increased pulmonary vascular resistance and RVF. This manuscript discusses the latest development of the previously published ovine PH-RVF model that utilizes left pulmonary artery (PA) ligation and main PA occlusion. This model of PH-RVF is a versatile platform to control not only the disease severity but also the RV's phenotypic response. Adult sheep (60-80 kg) underwent left PA (LPA) ligation, placement of main PA cuff, and insertion of RV pressure monitor. PA cuff and RV pressure monitor were connected to subcutaneous ports. Subjects underwent progressive PA banding twice per week for 9 weeks with sequential measures of RV pressure, PA cuff pressures, and mixed venous blood gas (SvO2). At the initiation and endpoint of this model, ventricular function and dimensions were assessed using echocardiography. In a representative group of 12 animal subjects, RV mean and systolic pressure increased from 28 ± 5 and 57 ± 7 mmHg at week 1, respectively, to 44 ± 7 and 93 ± 18 mmHg (mean ± standard deviation) by week 9. Echocardiography demonstrated characteristic findings of PH-RVF, notably RV dilation, increased wall thickness, and septal bowing. The longitudinal trend of SvO2 and PA cuff pressure demonstrates that the rate of PA banding can be titrated to elicit varying RV phenotypes. A faster PA banding strategy led to a precipitous decline in SvO2 < 65%, indicating RV decompensation, whereas a slower, more paced strategy led to the maintenance of physiologic SvO2 at 70%-80%. One animal that experienced the accelerated strategy developed several liters of pleural effusion and ascites by week 9. This chronic PH-RVF model provides a valuable tool for studying molecular mechanisms, developing diagnostic biomarkers, and enabling therapeutic innovation to manage RV adaptation and maladaptation from PH.

Entities:  

Mesh:

Year:  2021        PMID: 34338672      PMCID: PMC9096880          DOI: 10.3791/62694

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.424


  16 in total

1.  Large animal model of chronic pulmonary hypertension.

Authors:  Hitoshi Sato; Candice M Hall; Grant W Griffith; Kent F Johnson; John W McGillicuddy; Robert H Bartlett; Keith E Cook
Journal:  ASAIO J       Date:  2008 Jul-Aug       Impact factor: 2.872

2.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.

Authors:  Mariëlle C van de Veerdonk; Taco Kind; J Tim Marcus; Gert-Jan Mauritz; Martijn W Heymans; Harm-Jan Bogaard; Anco Boonstra; Koen M J Marques; Nico Westerhof; Anton Vonk-Noordegraaf
Journal:  J Am Coll Cardiol       Date:  2011-12-06       Impact factor: 24.094

Review 3.  Pleural effusions occurring with right heart failure.

Authors:  Anupama G Brixey; Richard W Light
Journal:  Curr Opin Pulm Med       Date:  2011-07       Impact factor: 3.155

4.  Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension.

Authors:  A Campo; S C Mathai; J Le Pavec; A L Zaiman; L K Hummers; D Boyce; T Housten; N Lechtzin; H Chami; R E Girgis; P M Hassoun
Journal:  Eur Respir J       Date:  2011-02-10       Impact factor: 16.671

5.  Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases.

Authors:  Yi-Feng Luo; Ivan M Robbins; Mevlut Karatas; Anupama G Brixey; Todd W Rice; Richard W Light
Journal:  Chest       Date:  2011-01-06       Impact factor: 9.410

6.  A low mortality model of chronic pulmonary hypertension in sheep.

Authors:  Joshua R Pohlmann; Begum Akay; Daniele Camboni; Kelly L Koch; Benjamin M Mervak; Keith E Cook
Journal:  J Surg Res       Date:  2011-04-09       Impact factor: 2.192

7.  Piglet model of chronic pulmonary hypertension.

Authors:  Olaf Mercier; Adriano Tivane; Peter Dorfmüller; Marc de Perrot; François Raoux; Benoît Decante; Saadia Eddahibi; Philippe Dartevelle; Elie Fadel
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

8.  Progression Toward Decompensated Right Ventricular Failure in the Ovine Pulmonary Hypertension Model.

Authors:  Rei Ukita; Andrew Tumen; John W Stokes; Christopher Pinelli; Kelsey R Finnie; Jennifer Talackine; Nancy L Cardwell; W Kelly Wu; Yatrik Patel; Emily J Tsai; Erika B Rosenzweig; Keith E Cook; Matthew Bacchetta
Journal:  ASAIO J       Date:  2022-02-01       Impact factor: 2.872

9.  Left Pulmonary Artery Ligation and Chronic Pulmonary Artery Banding Model for Inducing Right Ventricular-Pulmonary Hypertension in Sheep.

Authors:  Rei Ukita; Yuliya Tipograf; Andrew Tumen; Rachel Donocoff; John W Stokes; Neal M Foley; Jennifer Talackine; Nancy L Cardwell; Erika B Rosenzweig; Keith E Cook; Matthew Bacchetta
Journal:  ASAIO J       Date:  2021-01-01       Impact factor: 3.826

Review 10.  Large Animal Models of Heart Failure: A Translational Bridge to Clinical Success.

Authors:  Kleiton Augusto Santos Silva; Craig A Emter
Journal:  JACC Basic Transl Sci       Date:  2020-08-24
View more
  2 in total

Review 1.  The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.

Authors:  Olivier Boucherat; Vineet Agrawal; Allan Lawrie; Sebastien Bonnet
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

Review 2.  Preclinical models of congestive heart failure, advantages, and limitations for application in clinical practice.

Authors:  Marta Saura; Jose Luis Zamorano; Carlos Zaragoza
Journal:  Front Physiol       Date:  2022-08-04       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.